The
AMAS Test For Early Detection and Monitoring of Cancer
Most people are unaware
that there is a reliable, scientifically proven laboratory
blood test for detecting over 99% of all cancers. "Why
haven't the doctors I see ordered this test?" people
often ask me. Good question. I can only answer that this
is yet another example of the resistance to innovative
change that the medical establishment constantly demonstrates.
Most doctors are simply unaware of the AMAS test because
the powers that be ignore the test, and it remains largely
unknown.
AMAS stands for "anti-malignin
antibody in serum." The test is extremely sensitive;
blood levels of this antibody rise early in the course
of the vast majority of cancers of all types, regardless
of location in the body. The test is especially useful
when cancer is suspected but has not been confirmed by
a biopsy.
One study involving the
test was published in the journal Cancer
Detection and
Prevention in 1994. In 125 patients and controls, 118 were
subsequently diagnosed by the time the article was published.
In 21 individuals who were subsequently proven to have
cancer, the AMAS test was elevated. The test was normal
in 94, none of whom were shown to have cancer. In three
other subjects who did not have cancer, the test was elevated
when first done but a second test was normal. The other
seven subjects had positive AMAS tests but remained undiagnosed
at the time of the article, but all showed symptoms of
cancer that likely indicated its presence.
The study was consistent
with other published tests that indicate that the AMAS
test is over 95% reliable on the first test, and over 99%
reliable when a repeat test is performed. The test is a
standardized, validated assay, developed over 15 years
ago by Peter Bogovich, M.D., Ph.D. Dr. Bogovich has conducted
scores of studies and published widely on the test.
Another study published
in the Journal of Cellular
Biochemistry in 1994 stated
that levels typically rise with age and are higher in individuals
at high risk for cancer because of family history, but
stay within normal levels even when benign growths occur. "We
demonstrated that the concentration is most markedly increased
within weeks of the occurrence of malignant transformation
to clinical breast cancer," these researchers wrote.
This study involved breast cancer, but the test is valid
for all cancer types. Other researchers have written that
the test is an excellent screening method.
The AMAS test also is useful
in monitoring the treatment of malignancies. Levels typically
return to normal within two to three months of successful
treatment. Other biological markers in the blood are much
less specific and are usually not elevated early in the
course of disease or recurrence. Thus the AMAS test is
an excellent way to screen for and detect cancer or recurrences,
and to track treatment progress during treatment. Conventional
cancer treatment authorities are committed to a host of
expensive but highly profitable diagnostic (and treatment)
techniques (mammograms, MRIs, gastrointestinal series,
etc.). Were it not for the intransigence of established
authorities, the AMAS test undoubtedly would be much more
widely used.
The AMAS test should be
ordered and interpreted by a physician experienced with
the test. False negatives and positives do occur. The AMAS
test is available only to Dr. Schmid’s consultation
patients. For more information, please call our office. |
